相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys
Sally L. Huskinson et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2022)
Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration
E. Andrew Townsend
PSYCHOPHARMACOLOGY (2021)
The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats
C. Austin Zamarripa et al.
PSYCHOPHARMACOLOGY (2021)
Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys
C. Austin Zamarripa et al.
PSYCHOPHARMACOLOGY (2020)
Functional Selectivity and Antinociceptive Effects of a Novel KOPr Agonist
Andrea Bedini et al.
FRONTIERS IN PHARMACOLOGY (2020)
Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys
S. L. Huskinson et al.
PSYCHOPHARMACOLOGY (2020)
The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male rats
C. Austin Zamarripa et al.
BEHAVIOURAL PHARMACOLOGY (2020)
Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL/6J mice
Yong Zhang et al.
NEUROPHARMACOLOGY (2020)
Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion
Jeffrey J. Liu et al.
NEUROPSYCHOPHARMACOLOGY (2019)
A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Kendall L. Mores et al.
FRONTIERS IN PHARMACOLOGY (2019)
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses
Amelia D. Dunn et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine
Shane W. Kaski et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis
Saadet Inan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Therapeutic Potential of Kappa Opioid Agonists
Tyler C. Beck et al.
PHARMACEUTICALS (2019)
The analgesic and anti-inflammatory effects of Salvinorin A analogue -tetrahydropyran Salvinorin B in mice
K. F. Paton et al.
EUROPEAN JOURNAL OF PAIN (2017)
Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats
E. Andrew Townsend et al.
PSYCHOPHARMACOLOGY (2017)
Designing Safer Analgesics via μ-Opioid Receptor Pathways
H. C. Stephen Chan et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Insights from Preclinical Choice Models on Treating Drug Addiction
Matthew L. Banks et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses
Kenya Kamimura et al.
PLOS ONE (2017)
Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor
Selena S. Schattauer et al.
CELLULAR SIGNALLING (2017)
Biased agonism: An emerging paradigm in GPCR drug discovery
Zoran Rankovic et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria
Tarsis F. Brust et al.
SCIENCE SIGNALING (2016)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria
Tarsis F. Brust et al.
SCIENCE SIGNALING (2016)
Nalfurafine hydrochloride to treat pruritus: a review
Shigeki Inui
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2015)
Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys
Kevin B. Freeman et al.
PSYCHOPHARMACOLOGY (2014)
Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors
Lei Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects
Katherine A. MacLean et al.
PSYCHOPHARMACOLOGY (2013)
Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans
Mohini Ranganathan et al.
BIOLOGICAL PSYCHIATRY (2012)
Neuropharmacology of the Naturally Occurring κ-Opioid Hallucinogen Salvinorin A
Christopher W. Cunningham et al.
PHARMACOLOGICAL REVIEWS (2011)
Effects of Atypical kappa-Opioid Receptor Agonists on Intrathecal Morphine-Induced Itch and Analgesia in Primates
Mei-Chuan Ko et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
NALFURAFINE HYDROCHLORIDE: A NEW DRUG FOR THE TREATMENT OF UREMIC PRURITUS IN HEMODIALYSIS PATIENTS
Kaoru Nakao et al.
DRUGS OF TODAY (2009)
Mu/Kappa Opioid Interactions in Rhesus Monkeys: Implications for Analgesia and Abuse Liability
S. Stevens Negus et al.
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY (2008)
The novel κ-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice
M Tsuji et al.
LIFE SCIENCES (2001)
分享论文
